Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 8, 2007 - Issue 5
Submit an article Journal homepage
638
Views
59
CrossRef citations to date
0
Altmetric
Editorial

Angiotensin II reactivation and aldosterone escape phenomena in renin–angiotensin–aldosterone system blockade: is oral renin inhibition the solution?

Vasilios G Athyros 1Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece
,
Dimitri P Mikhailidis Department of Clinical Biochemistry (Vascular Prevention Clinic), Royal Free Hospital, Royal Free and University College Medical School, Pond Street, London NW3 2QG UK. [email protected]
,
Anna I Kakafika 1Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece
,
Konstantinos Tziomalos Department of Clinical Biochemistry (Vascular Prevention Clinic), Royal Free Hospital, Royal Free and University College Medical School, Pond Street, London NW3 2QG UK. [email protected]
&
Asterios Karagiannis 1Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece
Pages 529-535 | Published online: 22 Mar 2007

Citations (59)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (8)

Srikanth Yandrapalli, George Jolly, Medha Biswas, Yogita Rochlani, Prakash Harikrishnan, Wilbert S. Aronow & Gregg M. Lanier. (2018) Newer hormonal pharmacotherapies for heart failure. Expert Review of Endocrinology & Metabolism 13:1, pages 35-49.
Read now
Jasmina Varagic, Henry Punzi & Carlos M Ferrario. (2014) Clinical utility of fixed-dose combinations in hypertension: evidence for the potential of nebivolol/valsartan. Integrated Blood Pressure Control 7, pages 61-70.
Read now
John E. Moulder, Eric P. Cohen & Brian L. Fish. (2014) Mitigation of experimental radiation nephropathy by renin-equivalent doses of angiotensin converting enzyme inhibitors. International Journal of Radiation Biology 90:9, pages 762-768.
Read now
Scott S Billecke & Pamela A Marcovitz. (2013) Long-term safety and efficacy of telmisartan/amlodipine single pill combination in the treatment of hypertension. Vascular Health and Risk Management 9, pages 95-104.
Read now
Roberto Ferrari & Eric Boersma. (2013) The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review. Expert Review of Cardiovascular Therapy 11:6, pages 705-717.
Read now
Abdul Ali Abdellatif. (2012) The role of renin inhibition in treating the hypertensive patient with diabetes: a summary of preclinical and clinical evidence. Expert Review of Cardiovascular Therapy 10:2, pages 251-263.
Read now
Dimitris Tousoulis, Nikolaos Papageorgiou, Emmanouil Androulakis, Kiriaki Paroutoglou & Christodoulos Stefanadis. (2010) Novel therapeutic strategies targeting vascular endothelium in essential hypertension. Expert Opinion on Investigational Drugs 19:11, pages 1395-1412.
Read now
David W Laight. (2009) Therapeutic inhibition of the renin angiotensin aldosterone system. Expert Opinion on Therapeutic Patents 19:6, pages 753-759.
Read now

Articles from other publishers (51)

Yaling Zhang, Song Ren, Yuan Zhang, Li Wang & Guisen Li. (2023) Efficacy and safety of dual blockade of the renin-angiotensin-aldosterone system in diabetic kidney disease: A meta-analysis. Diabetic Nephropathy 3:2, pages 29-39.
Crossref
Fred Stephen Sarfo & Bruce Ovbiagele. (2022) Promise of Physiological Profiling to Prevent Stroke in People of African Ancestry: Prototyping Ghana. Current Neurology and Neuroscience Reports 22:11, pages 735-743.
Crossref
Debargha Basuli, Rohan Umesh Parekh, Acacia White, Abdullah Thayyil & Srinivas Sriramula. (2022) Kinin B1 Receptor Mediates Renal Injury and Remodeling in Hypertension. Frontiers in Medicine 8.
Crossref
José Wilson N. Corrêa, Karoline R. Boaro, Letícia B. Sene, Juliano Z. Polidoro, Thiago A. Salles, Flavia L. Martins, Lusiane M. Bendhack & Adriana C. C. Girardi. (2021) Antiproteinuric and Hyperkalemic Mechanisms Activated by Dual Versus Single Blockade of the RAS in Renovascular Hypertensive Rats. Frontiers in Physiology 12.
Crossref
Iwona Baranowska, Olga Gawrys, Malwina M. Roszkowska-Chojecka, Bozena Badzynska, Dagmara Tymecka, Krzysztof H. Olszynski & Elzbieta Kompanowska-Jezierska. (2021) Chymase Dependent Pathway of Angiotensin II Generation and Rapeseed Derived Peptides for Antihypertensive Treatment of Spontaneously Hypertensive Rats. Frontiers in Pharmacology 12.
Crossref
Fabrizio Pucci, Philippe Bogaerts & Marianne Rooman. (2020) Modeling the Molecular Impact of SARS-CoV-2 Infection on the Renin-Angiotensin System. Viruses 12:12, pages 1367.
Crossref
Erdal Topparmak, Sevda Tanrıkulu-Küçük, Hikmet Koçak & Yıldız Öner-İyidoğan. (2020) Serum chymase levels in obese individuals: the relationship with inflammation and hypertension. Turkish Journal of Biochemistry 45:3, pages 305-314.
Crossref
Vajir Malek, Sachin V. Suryavanshi, Nisha Sharma, Yogesh A. Kulkarni, Shrikant R. Mulay & Anil Bhanudas Gaikwad. 2021. Reviews of Physiology, Biochemistry and Pharmacology. Reviews of Physiology, Biochemistry and Pharmacology 31 71 .
L. Lauder, S. Ewen, I. E. Emrich, M. Böhm & F. Mahfoud. (2019) Kardiovaskuläre Pharmakotherapie und koronare Revaskularisation bei terminaler NiereninsuffizienzCardiovascular pharmacotherapy and coronary revascularization in end-stage renal failure. Herz 44:7, pages 611-629.
Crossref
Urszula Tyrankiewicz, Agnieszka Kij, Tasnim Mohaissen, Mariola Olkowicz, Ryszard T. Smolenski & Stefan Chlopicki. 2019. Aldosterone-Mineralocorticoid Receptor - Cell Biology to Translational Medicine. Aldosterone-Mineralocorticoid Receptor - Cell Biology to Translational Medicine.
Johannes J. Kovarik, Christopher C. Kaltenecker, Chantal Kopecky, Oliver Domenig, Marlies Antlanger, Johannes Werzowa, Farsad Eskandary, Renate Kain, Marko Poglitsch, Sabine Schmaldienst, Georg A. Böhmig & Marcus D. Säemann. (2019) Intrarenal Renin-Angiotensin-System Dysregulation after Kidney Transplantation. Scientific Reports 9:1.
Crossref
Yanhuan Feng, Rongshuang Huang, Janet Kavanagh, Lingzhi Li, Xiaoxi Zeng, Yi Li & Ping Fu. (2019) Efficacy and Safety of Dual Blockade of the Renin–Angiotensin–Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis. American Journal of Cardiovascular Drugs 19:3, pages 259-286.
Crossref
Lan Wang, Chi Liu, Xiru Chen & Peng Li. (2019) Alamandine attenuates long‑term hypertension‑induced cardiac fibrosis independent of blood pressure. Molecular Medicine Reports.
Crossref
Francesco Spannella, Federico Giulietti, Paolo Balietti, Elisabetta Borioni, Francesca E. Lombardi, Maddalena Ricci, Guido Cocci, Laura Landi & Riccardo Sarzani. (2017) Plasma renin activity to plasma aldosterone concentration ratio correlates with night-time and pulse pressures in essential hypertensive patients treated with angiotensin-converting enzyme inhibitors/AT1 blockers. Journal of Hypertension 35:11, pages 2315-2322.
Crossref
Vajir Malek & Anil Bhanudas Gaikwad. (2017) Neprilysin inhibitors: A new hope to halt the diabetic cardiovascular and renal complications?. Biomedicine & Pharmacotherapy 90, pages 752-759.
Crossref
Milton Packer & John J V McMurray. (2017) Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure. The Lancet 389:10081, pages 1831-1840.
Crossref
Dong Ming, Liao Songyan, Chen Yawen, Zheng Na, Ma Jing, Xiao Zhaowen, Liu Ye, Ding Wa & Liu Jie. (2017) trans-Polydatin protects the mouse heart against ischemia/reperfusion injury via inhibition of the renin–angiotensin system (RAS) and Rho kinase (ROCK) activity. Food & Function 8:6, pages 2309-2321.
Crossref
Alexandru Burlacu & Adrian Covic. 2017. Resistant Hypertension in Chronic Kidney Disease. Resistant Hypertension in Chronic Kidney Disease 89 126 .
Anna Gromotowicz-Poplawska, Piotr Szoka, Patrycjusz Kolodziejczyk, Karol Kramkowski, Marzena Wojewodzka-Zelezniakowicz & Ewa Chabielska. (2016) New agents modulating the renin-angiotensin-aldosterone system—Will there be a new therapeutic option?. Experimental Biology and Medicine 241:17, pages 1888-1899.
Crossref
Shahid Nadeem & Donald L. Batisky. (2013) Aliskiren, the first direct renin inhibitor: assessing a role in pediatric hypertension and kidney diseases. Pediatric Nephrology 29:11, pages 2105-2111.
Crossref
Ramapriya Sinnakirouchenan & Theodore A. Kotchen. (2014) Role of Sodium Restriction and Diuretic Therapy for “Resistant” Hypertension in Chronic Kidney Disease. Seminars in Nephrology 34:5, pages 514-519.
Crossref
Arnold B. AlperJr.Jr.. 2014. Diabetes and Kidney Disease. Diabetes and Kidney Disease 29 38 .
Henry Krum, Barrie Massie, William T. Abraham, Kenneth Dickstein, Lars Kober & John J.V. McMurray. (2014) Losing ALTITUDE? How should ASTRONAUT launch into ATMOSPHERE. European Journal of Heart Failure 15:11, pages 1205-1207.
Crossref
Joel M. Neutel & David H. G. Smith. (2013) Hypertension Management: Rationale for Triple Therapy Based on Mechanisms of Action. Cardiovascular Therapeutics 31:5, pages 251-258.
Crossref
Iveta Herichová, Dorota Šoltésová, Kristína Szántóová, Boris Mravec, Denisa Neupauerová, Anna Veselá & Michal Zeman. (2013) Effect of angiotensin II on rhythmic per2 expression in the suprachiasmatic nucleus and heart and daily rhythm of activity in Wistar rats. Regulatory Peptides 186, pages 49-56.
Crossref
Rania A Elrashidy, Mervat E Asker & Hoda E Mohamed. (2012) Beneficial effects of pioglitazone against cardiovascular injury are enhanced by combination with aliskiren in a rat model of diabetic nephropathy. Journal of Pharmacy and Pharmacology 64:6, pages 862-871.
Crossref
J. David Spence. (2012) Lessons From Africa: The Importance of Measuring Plasma Renin and Aldosterone in Resistant Hypertension. Canadian Journal of Cardiology 28:3, pages 254-257.
Crossref
Nadja Grobe, Khalid M. Elased, David R. Cool & Mariana Morris. (2012) Mass spectrometry for the molecular imaging of angiotensin metabolism in kidney. American Journal of Physiology-Endocrinology and Metabolism 302:8, pages E1016-E1024.
Crossref
Pantelis A Sarafidis & Luis M Ruilope. (2012) Cardiorenal disease development under chronic renin–angiotensin–aldosterone system suppression. Journal of the Renin-Angiotensin-Aldosterone System 13:1, pages 217-219.
Crossref
Anjay Rastogi, Mohamad Rashid & Richard F. Wright. (2011) Reducing Cardiorenal Risk Through Combination Therapy With a Direct Renin Inhibitor. The Journal of Clinical Hypertension 13:11, pages 848-855.
Crossref
Maya GuglinOlga Kristof-Kuteyeva, Irina Novotorova & Pravin Pratap. (2010) Aldosterone Antagonists in Heart Failure. Journal of Cardiovascular Pharmacology and Therapeutics 16:2, pages 150-159.
Crossref
Junichi Yatabe, Minoru Yoneda, Midori S. Yatabe, Tsuyoshi Watanabe, Robin A. Felder, Pedro A. Jose & Hironobu Sanada. (2011) Angiotensin III Stimulates Aldosterone Secretion from Adrenal Gland Partially via Angiotensin II Type 2 Receptor But Not Angiotensin II Type 1 Receptor. Endocrinology 152:4, pages 1582-1588.
Crossref
Erin Elizabeth Kelland, Leanne Michelle McAuley & Guido Filler. (2010) Are we ready to use aliskiren in children?. Pediatric Nephrology 26:3, pages 473-477.
Crossref
Luis M. Ruilope. (2010) On the Need to Reissue Renin-Angiotensin-Aldosterone System Suppression in Chronic Kidney Disease. Current Cardiovascular Risk Reports 5:1, pages 5-6.
Crossref
Jian-Zhong Sun, Long-Hui Cao & Hong Liu. (2010) ACE inhibitors in cardiac surgery: current studies and controversies. Hypertension Research 34:1, pages 15-22.
Crossref
Marvin A. Konstam & Richard D. Patten. 2011. Heart Failure: A Companion to Braunwald's Heart Disease. Heart Failure: A Companion to Braunwald's Heart Disease 659 673 .
Daniel F. Catanzaro & William H. Frishman. (2010) Angiotensin Receptor Blockers for Management of Hypertension. Southern Medical Journal 103:7, pages 669-673.
Crossref
Carlos M. Ferrario. (2010) Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin–angiotensin–aldosterone system: Antihypertensive effects and benefits beyond BP control. Life Sciences 86:9-10, pages 289-299.
Crossref
Mordchai Ravid. (2009) Dual Blockade of the Renin-Angiotensin System in Diabetic Nephropathy. Diabetes Care 32:suppl_2, pages S410-S413.
Crossref
Gaurav Jain, Ruth C. Campbell & David G. Warnock. (2009) Mineralocorticoid Receptor Blockers and Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology 4:10, pages 1685-1691.
Crossref
Yasmin Pasha, Paul Gusbeth-Tatomir, Adrian Covic & David Goldsmith. (2009) Direct renin inhibitors: ONTARGET for success?. International Urology and Nephrology 41:2, pages 341-355.
Crossref
Michael J Ryan & Katherine R Tuttle. (2008) Elevations in serum creatinine with RAAS blockade: why isnʼt it a sign of kidney injury?. Current Opinion in Internal Medicine 7:6, pages 599-605.
Crossref
Michael J Ryan & Katherine R Tuttle. (2008) Elevations in serum creatinine with RAAS blockade: why isnʼt it a sign of kidney injury?. Current Opinion in Nephrology and Hypertension 17:5, pages 443-449.
Crossref
Jan H Schefe, Christian Neumann, Matthias Goebel, Jan Danser, Sebastian Kirsch, Ronald Gust, Ulrich Kintscher, Thomas Unger & Heiko Funke-Kaiser. (2008) Prorenin engages the (pro)renin receptor like renin and both ligand activities are unopposed by aliskiren. Journal of Hypertension 26:9, pages 1787-1794.
Crossref
Y Hong, J Dingemanse & DE Mager. (2008) Pharmacokinetic/Pharmacodynamic Modeling of Renin Biomarkers in Subjects Treated With the Renin Inhibitor Aliskiren. Clinical Pharmacology & Therapeutics 84:1, pages 136-143.
Crossref
Jamal Ahmad. (2008) Renin–angiotensin system blockade in diabetic nephropathy. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2:2, pages 135-158.
Crossref
Hussam Abuissa & James O’Keefe. (2008) The role of renin–angiotensin–aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection. Diabetes, Obesity and Metabolism 0:0, pages 080520205432340-???.
Crossref
John M. C. Connell, Scott M. MacKenzie, E. Marie Freel, Robert Fraser & Eleanor Davies. (2008) A Lifetime of Aldosterone Excess: Long-Term Consequences of Altered Regulation of Aldosterone Production for Cardiovascular Function. Endocrine Reviews 29:2, pages 133-154.
Crossref
. (2007) Bibliography—Editors' selection of current world literature. Coronary Artery Disease 18:6, pages 501-506.
Crossref
Andrew S Bomback & Philip J Klemmer. (2007) The incidence and implications of aldosterone breakthrough. Nature Clinical Practice Nephrology 3:9, pages 486-492.
Crossref
G.K. Aulakh, R.K. Sodhi & M. Singh. (2007) An update on non-peptide angiotensin receptor antagonists and related RAAS modulators. Life Sciences 81:8, pages 615-639.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.